Cargando…

Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants

Background: The recently emerged SARS-CoV-2 B.1.1.529 lineage and its sublineages (Omicron variant) pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available monoclonal antibody therapies. RT-PCR-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Nörz, Dominik, Grunwald, Moritz, Tang, Hui Ting, Weinschenk, Celine, Günther, Thomas, Robitaille, Alexis, Giersch, Katja, Fischer, Nicole, Grundhoff, Adam, Aepfelbacher, Martin, Pfefferle, Susanne, Lütgehetmann, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950896/
https://www.ncbi.nlm.nih.gov/pubmed/35337015
http://dx.doi.org/10.3390/v14030608
_version_ 1784675253110177792
author Nörz, Dominik
Grunwald, Moritz
Tang, Hui Ting
Weinschenk, Celine
Günther, Thomas
Robitaille, Alexis
Giersch, Katja
Fischer, Nicole
Grundhoff, Adam
Aepfelbacher, Martin
Pfefferle, Susanne
Lütgehetmann, Marc
author_facet Nörz, Dominik
Grunwald, Moritz
Tang, Hui Ting
Weinschenk, Celine
Günther, Thomas
Robitaille, Alexis
Giersch, Katja
Fischer, Nicole
Grundhoff, Adam
Aepfelbacher, Martin
Pfefferle, Susanne
Lütgehetmann, Marc
author_sort Nörz, Dominik
collection PubMed
description Background: The recently emerged SARS-CoV-2 B.1.1.529 lineage and its sublineages (Omicron variant) pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available monoclonal antibody therapies. RT-PCR-based variant tests can be used to screen large sample-sets rapidly and accurately for relevant variants of concern (VOC). The aim of this study was to establish and validate a multiplex assay on the cobas 6800/8800 systems to allow discrimination between the two currently circulating VOCs, Omicron and Delta, in clinical samples. Methods: Primers and probes were evaluated for multiplex compatibility. Analytic performance was assessed using cell culture supernatant of an Omicron variant isolate and a clinical Delta variant sample, normalized to WHO-Standard. Clinical performance of the multiplex assay was benchmarked against NGS results. Results: In silico testing of all oligos showed no interactions with a high risk of primer-dimer formation or amplification of human DNA/RNA. Over 99.9% of all currently available Omicron variant sequences are a perfect match for at least one of the three Omicron targets included in the multiplex. Analytic sensitivity was determined as 19.0 IU/mL (CI95%: 12.9–132.2 IU/mL) for the A67V + del-HV69-70 target, 193.9 IU/mL (CI95%: 144.7–334.7 IU/mL) for the E484A target, 35.5 IU/mL (CI95%: 23.3–158.0 IU/mL) for the N679K + P681H target and 105.0 IU/mL (CI95%: 80.7–129.3 IU/mL) for the P681R target. All sequence variances were correctly detected in the clinical sample set (225/225 Targets). Conclusion: RT-PCR-based variant screening compared to whole genome sequencing is both rapid and reliable in detecting relevant sequence variations in SARS-CoV-2 positive samples to exclude or verify relevant VOCs. This allows short-term decision-making, e.g., for patient treatment or public health measures.
format Online
Article
Text
id pubmed-8950896
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89508962022-03-26 Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants Nörz, Dominik Grunwald, Moritz Tang, Hui Ting Weinschenk, Celine Günther, Thomas Robitaille, Alexis Giersch, Katja Fischer, Nicole Grundhoff, Adam Aepfelbacher, Martin Pfefferle, Susanne Lütgehetmann, Marc Viruses Article Background: The recently emerged SARS-CoV-2 B.1.1.529 lineage and its sublineages (Omicron variant) pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available monoclonal antibody therapies. RT-PCR-based variant tests can be used to screen large sample-sets rapidly and accurately for relevant variants of concern (VOC). The aim of this study was to establish and validate a multiplex assay on the cobas 6800/8800 systems to allow discrimination between the two currently circulating VOCs, Omicron and Delta, in clinical samples. Methods: Primers and probes were evaluated for multiplex compatibility. Analytic performance was assessed using cell culture supernatant of an Omicron variant isolate and a clinical Delta variant sample, normalized to WHO-Standard. Clinical performance of the multiplex assay was benchmarked against NGS results. Results: In silico testing of all oligos showed no interactions with a high risk of primer-dimer formation or amplification of human DNA/RNA. Over 99.9% of all currently available Omicron variant sequences are a perfect match for at least one of the three Omicron targets included in the multiplex. Analytic sensitivity was determined as 19.0 IU/mL (CI95%: 12.9–132.2 IU/mL) for the A67V + del-HV69-70 target, 193.9 IU/mL (CI95%: 144.7–334.7 IU/mL) for the E484A target, 35.5 IU/mL (CI95%: 23.3–158.0 IU/mL) for the N679K + P681H target and 105.0 IU/mL (CI95%: 80.7–129.3 IU/mL) for the P681R target. All sequence variances were correctly detected in the clinical sample set (225/225 Targets). Conclusion: RT-PCR-based variant screening compared to whole genome sequencing is both rapid and reliable in detecting relevant sequence variations in SARS-CoV-2 positive samples to exclude or verify relevant VOCs. This allows short-term decision-making, e.g., for patient treatment or public health measures. MDPI 2022-03-15 /pmc/articles/PMC8950896/ /pubmed/35337015 http://dx.doi.org/10.3390/v14030608 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nörz, Dominik
Grunwald, Moritz
Tang, Hui Ting
Weinschenk, Celine
Günther, Thomas
Robitaille, Alexis
Giersch, Katja
Fischer, Nicole
Grundhoff, Adam
Aepfelbacher, Martin
Pfefferle, Susanne
Lütgehetmann, Marc
Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants
title Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants
title_full Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants
title_fullStr Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants
title_full_unstemmed Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants
title_short Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants
title_sort clinical evaluation of a fully-automated high-throughput multiplex screening-assay to detect and differentiate the sars-cov-2 b.1.1.529 (omicron) and b.1.617.2 (delta) lineage variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950896/
https://www.ncbi.nlm.nih.gov/pubmed/35337015
http://dx.doi.org/10.3390/v14030608
work_keys_str_mv AT norzdominik clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT grunwaldmoritz clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT tanghuiting clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT weinschenkceline clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT guntherthomas clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT robitaillealexis clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT gierschkatja clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT fischernicole clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT grundhoffadam clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT aepfelbachermartin clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT pfefferlesusanne clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants
AT lutgehetmannmarc clinicalevaluationofafullyautomatedhighthroughputmultiplexscreeningassaytodetectanddifferentiatethesarscov2b11529omicronandb16172deltalineagevariants